In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.09, marking a -1.42% move from the previous day. This change lagged the S&P 500's daily gain of 0.52%. Meanwhile, the Dow gained 0.63% ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge ...

Depression and anxiety are the most common psychiatric disorders in the world. Around 300 million people suffer from ...

A court has approved the $305m sale of 23andMe’s assets to a nonprofit led by former 23andMe CEO Anne Wojcicki.

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that ...

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Genetics plays a crucial role in reproductive medicine, impacting both fertility and the health of offspring. According to ...

While physical activity is known to slow cognitive decline in Alzheimer’s disease, many patients are unable to exercise due ...

Through an effort led by Wisconsin’s two medical schools, newborn genomic testing capacity will expand to more hospitals ...

Tulane University researchers created a first-of-its-kind subcellular map of an area of the brain commonly affected by ...

At 69, marathoner Mike Fremont was given three months to live after a colorectal cancer diagnosis. He credits a radical diet ...

The totality of bacteria, viruses and fungi that exist in and on a multicellular organism forms its natural microbiome. The ...